CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company will present new preclinical data identifying potential biomarkers predictive of response to SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical trial in advanced solid tumors, at the San Antonio Breast Cancer Symposium (SABCS) taking place December 5-9 in San Antonio. The Company will also present on the use of its gene control platform to analyze regulatory regions of the genome in triple negative breast cancer cells and identify potential new drug targets.
Details on the presentations are as follows:
Date & Time: Wednesday, December 6, from 5-7 p.m. CST
Presentation
Title: BCL2L1 (BCL-XL) expression and MYC super-enhancer
positivity predict sensitivity to the covalent CDK7 inhibitor SY-1365 in
triple negative breast cancer (TNBC) cell lines
Session Title:
Treatment: Novel Targets and Targeted agents
Presenter: Nisha
Rajagopal, Ph.D., Senior Scientist, Syros
Abstract Number: 1343
Location:
Henry B. Gonzalez Convention Center, Hall 1
Date & Time: Thursday, December 7, from 7-9 a.m. CST
Presentation
Title: Epigenomic analysis of cancer stem cell (CSC)-enriched
triple-negative breast cancer (TNBC) populations reveals gene regulatory
circuitry and novel tumor cell vulnerabilities
Session Title: Tumor
cell and molecular biology: Epigenetics
Presenter: Matthew
Guenther, Ph.D., Principal Scientist, Syros
Abstract Number: 1548
Location:
Henry B. Gonzalez Convention Center, Hall 1
About Syros Pharmaceuticals
Syros Pharmaceuticals is
pioneering the understanding of the non-coding region of the genome to
advance a new wave of medicines that control expression of
disease-driving genes. Syros has built a proprietary platform that is
designed to systematically and efficiently analyze this unexploited
region of DNA in human disease tissue to identify and drug novel targets
linked to genomically defined patient populations. Because gene
expression is fundamental to the function of all cells, Syros’ gene
control platform has broad potential to create medicines that achieve
profound and durable benefit across a range of diseases. Syros is
currently focused on cancer and immune-mediated diseases and is
advancing a growing pipeline of gene control medicines. Syros’ lead drug
candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical
trial for genomically defined subsets of patients with acute myeloid
leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7
inhibitor in a Phase 1 clinical trial for patients with advanced solid
tumors, including transcriptionally dependent cancers such as triple
negative breast, small cell lung and ovarian cancers. Led by a team with
deep experience in drug discovery, development and commercialization,
Syros is located in Cambridge, Mass.
Cautionary Note Regarding Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, including without
limitation statements regarding theutility of potential biomarkers of
response to SY-1365; the ability to identify new breast cancer targets;
and the benefits of Syros’ gene control platform. The words
‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’
‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’
‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions
are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Actual
results or events could differ materially from the plans, intentions and
expectations disclosed in these forward-looking statements as a result
of various important factors, including Syros’ ability to: advance the
development of its programs, including SY-1425 and SY-1365, under the
timelines it projects in current and future clinical trials; demonstrate
in any current and future clinical trials the requisite safety, efficacy
and combinability of its drug candidates; replicate scientific and
non-clinical data in clinical trials; successfully develop a companion
diagnostic test to identify patients with relevant predictive
biomarkers; obtain and maintain patent protection for its drug
candidates and the freedom to operate under third party intellectual
property; obtain and maintain necessary regulatory approvals; identify,
enter into and maintain collaboration agreements with third parties;
manage competition; manage expenses; raise the substantial additional
capital needed to achieve its business objectives; attract and retain
qualified personnel; and successfully execute on its business
strategies; risks described under the caption “Risk Factors” in Syros’
Quarterly Report on Form 10-Q for the quarter ended September 30, 2017,
which is on file with the Securities and Exchange Commission; and risks
described in other filings that Syros makes with the Securities and
Exchange Commission in the future. Any forward-looking statements
contained in this press release speak only as of the date hereof, and
Syros expressly disclaims any obligation to update any forward-looking
statements, whether because of new information, future events or
otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171113005263/en/
Media Contact:
Syros Pharmaceuticals
Naomi Aoki,
617-283-4298
naoki@syros.com
or
Investor
Contact:
Stern Investor Relations, Inc.
Hannah
Deresiewicz, 212-362-1200
hannahd@sternir.com
Source: Syros Pharmaceuticals
Released November 13, 2017